Wellington Management Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $984K | Sell |
707,745
-78,720
| -10% | -$108K | ﹤0.01% | 1679 |
|
|
2025
Q4 | $1.27M | Sell |
786,465
-83,339
| -10% | -$174K | ﹤0.01% | 1676 |
|
|
2025
Q3 | $2.37M | Buy |
869,804
+174,076
| +25% | +$579K | ﹤0.01% | 1589 |
|
|
2025
Q2 | $2.53M | Buy |
695,728
+29,161
| +4% | +$80.1K | ﹤0.01% | 1521 |
|
|
2025
Q1 | $1.28M | Buy |
666,567
+164,440
| +33% | +$336K | ﹤0.01% | 1648 |
|
|
2024
Q4 | $954K | Buy |
502,127
+97,409
| +24% | +$169K | ﹤0.01% | 1726 |
|
|
2024
Q3 | $534K | Buy |
+404,718
| New | +$540K | ﹤0.01% | 1809 |
|
|
2022
Q2 | – | Sell |
-316,863
| Closed | -$227K | – | 2064 |
|
|
2022
Q1 | $227K | Buy |
316,863
+2,801
| +0.9% | +$5.99K | ﹤0.01% | 2061 |
|
|
2021
Q4 | $710K | Buy |
+314,062
| New | +$856K | ﹤0.01% | 1872 |
|
|
2021
Q3 | – | Sell |
-10,736,859
| Closed | -$40.7M | – | 2143 |
|
|
2021
Q2 | $40.7M | Sell |
10,736,859
-101,306
| -0.9% | -$341K | 0.01% | 887 |
|
|
2021
Q1 | $36.7M | Sell |
10,838,165
-1,752,298
| -14% | -$6.31M | 0.01% | 901 |
|
|
2020
Q4 | $35.3M | Buy |
12,590,463
+4,665,491
| +59% | +$13.6M | 0.01% | 875 |
|
|
2020
Q3 | $19.9M | Buy |
7,924,972
+650,249
| +9% | +$5.71M | ﹤0.01% | 952 |
|
|
2020
Q2 | $98.8M | Buy |
7,274,723
+5,549,182
| +322% | +$57.4M | 0.02% | 526 |
|
|
2020
Q1 | $13.1M | Buy |
1,725,541
+828,814
| +92% | +$6.45M | ﹤0.01% | 978 |
|
|
2019
Q4 | $5.67M | Buy |
896,727
+496,434
| +124% | +$2.36M | ﹤0.01% | 1305 |
|
|
2019
Q3 | $1.57M | Sell |
400,293
-10,065
| -2% | -$43.1K | ﹤0.01% | 1642 |
|
|
2019
Q2 | $1.99M | Sell |
410,358
-69
| -0% | -$393 | ﹤0.01% | 1629 |
|
|
2019
Q1 | $3.36M | Buy |
410,427
+519
| +0.1% | +$3.56K | ﹤0.01% | 1480 |
|
|
2018
Q4 | $2.27M | Buy |
409,908
+75
| +0% | +$587 | ﹤0.01% | 1608 |
|
|
2018
Q3 | $3.62M | Sell |
409,833
-156,024
| -28% | -$1.4M | ﹤0.01% | 1558 |
|
|
2018
Q2 | $5.65M | Sell |
565,857
-77,227
| -12% | -$773K | ﹤0.01% | 1455 |
|
|
2018
Q1 | $6.13M | Buy |
643,084
+266,158
| +71% | +$3.72M | ﹤0.01% | 1417 |
|
|
2017
Q4 | $5.61M | Buy |
376,926
+63,945
| +20% | +$1.06M | ﹤0.01% | 1444 |
|
|
2017
Q3 | $6.16M | Buy |
312,981
+122,545
| +64% | +$1.88M | ﹤0.01% | 1415 |
|
|
2017
Q2 | $2.74M | Buy |
190,436
+38,416
| +25% | +$487K | ﹤0.01% | 1617 |
|
|
2017
Q1 | $1.4M | Buy |
152,020
+22,520
| +17% | +$220K | ﹤0.01% | 1833 |
|
|
2016
Q4 | $1.35M | Sell |
129,500
-13,830
| -10% | -$119K | ﹤0.01% | 1798 |
|
|
2016
Q3 | $1.3M | Hold |
143,330
| – | – | ﹤0.01% | 1777 |
|
|
2016
Q2 | $1.07M | Sell |
143,330
-2,070
| -1% | -$18.1K | ﹤0.01% | 1766 |
|
|
2016
Q1 | $1.31M | Buy |
+145,400
| New | +$1.18M | ﹤0.01% | 1721 |
|
Other funds holding AKBA
VCM
VPM
Wellington Management Group's AKBA Position: Q1 2026 in Review
Wellington Management Group reduced its Akebia Therapeutics (AKBA) stake by 10% in Q1 2026, selling an estimated $108K and leaving 707,745 shares worth $984K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.
Wellington Management Group first reported a position in AKBA in Q1 2016 and has held it in 31 quarters since. The position peaked at $98.8M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Wellington Management Group held 707,745 shares of Akebia Therapeutics worth $984K as of Q1 2026.
- Wellington Management Group sold 78,720 Akebia Therapeutics shares in Q1 2026, an estimated $108K.
- Akebia Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1679 holding.
- Wellington Management Group first reported a position in Akebia Therapeutics in Q1 2016 and has held it in 31 quarters since.
- Wellington Management Group's Akebia Therapeutics position peaked at $98.8M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.